Tuesday, August 13, 2013: 8:30 AM-11:30 AM
Nautilus 5 (Sheraton San Diego)
Convener:
Tom Kelleher - Amgen, Thousand Oaks, CA
Co-Convener:
Tiffany D. Rau - Eli Lilly, Lake Charles, LA
8:30 AM
Biosimilar MAb Production in Stainless Steel and Single-Use Bioreactors
H. Henry Lamb1, Sharyn L. Farnsworth2 and Stewart McNaull2, (1)Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, NC, (2)Upstream Process Development, Fujifilm Diosynth Biotechnologies, Cary, NC
H. Henry Lamb1, Sharyn L. Farnsworth2 and Stewart McNaull2, (1)Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, NC, (2)Upstream Process Development, Fujifilm Diosynth Biotechnologies, Cary, NC
9:00 AM
A leachable compound in plastic bioprocess equipment that is detrimental to cell growth
Matthew Hammond, Amgen Inc, Thousand Oaks, CA
Matthew Hammond, Amgen Inc, Thousand Oaks, CA
10:00 AM
Scale Free Manufacturing Model using Perfusion
Gael Peron1, Wilson Lee1 and Olivier Berteau2, (1)Charter Medical, Ltd, Winston-Salem, NC, (2)APIcells Inc, Lowell, MA
Gael Peron1, Wilson Lee1 and Olivier Berteau2, (1)Charter Medical, Ltd, Winston-Salem, NC, (2)APIcells Inc, Lowell, MA
10:30 AM
Impact of Regulatory Guidances on Biopharmaceutical Cell Culture
Tom Kelleher, Global Process Engineering and Process Development, Amgen, Thousand Oaks, CA
Tom Kelleher, Global Process Engineering and Process Development, Amgen, Thousand Oaks, CA
11:00 AM
Challenges Faced During the Flublok Approval Process
Penny Post, Regulatory, Protein Sciences Corporation, Meriden, CT
Penny Post, Regulatory, Protein Sciences Corporation, Meriden, CT
See more of: Invited Oral Papers